Rubicon to Present at the 2016 BioInvestor Forum
Category : Fv-Hsp72
Lake Forest, CA (October 12th, 2016) – Richard Richieri, COO of Rubicon Biotechnology, will be presenting at the BioInvestor Forum in San Francisco, CA on Oct 18th, 2016. The presentation titled “Developing a Treatment for Heart Attack Victims” will showcase Rubicon’s development of our novel Fv-Hsp72 protein. Fv-Hsp72 targets areas suffering from acute damage and delivers Hsp72 directly into damaged cells and was tested in a myocardial infarction animal model at Mount Sinai Medical Center. Myocardial cells affected by the infarction that endure significant levels of oxidative stress during reperfusion can be irreparably damaged. Our data from the Mount Sinai study showed statistically significant reduction in heart damage as measured by SPECT imaging and improved heart function as measured by the left ventricle ejection fraction. Lower levels of a blood biomarker, cardiac Troponin I, also corroborated the difference in damage between Fv-Hsp70 treated rabbits and controls. Rubicon, intends to begin clinical development of Fv-Hsp70 in myocardial infarction using our network of CROs, CMOs and collaborators.
About Rubicon Biotechnology
Rubicon Biotechnology is a privately held biotechnology company that develops targeted, life-saving technologies in the areas of defense countermeasures, cardiology, neurology and oncology. Rubicon has in-licensed two platform technologies for drug development. The first is “Antibody Mediated Transduction of Heat Shock Proteins into Living Cells” from the Veterans Administration. This technology delivers heat shock protein, a key protein which saves injured cells that suffer hypoxic and oxidative stresses that unfortunately occur following common tissue injuries, such as heart attack, stroke and traumatic brain injury. The second technology, “Modified Non-Internalizing A5 Variants,” licensed from MosaMedix B.V., delivers immunostimulants to tumors in order to enhance the immune system’s ability to fight cancer. With support from several SBIR and CounterACT grants, and in collaboration with major institutions in the U.S., Rubicon is developing these targeted therapies with the goal of improving health outcomes and saving lives.